Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...
The French pharma group has filed anti-CD38 antibody Sarclisa (isatuximab) for use in combination with Takeda’s Velcade (bortezomib), lenalidomide, and dexamethasone – known as the VRd regimen ...
With this nod, Sarclisa is now approved in combination with Velcade (bortezomib), Bristol Myers’ BMY Revlimid (lenalidomide) ...